OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) is a
clinical-stage biopharmaceutical company engaged in the development of novel
cancer immunotherapy products. The company’s lead product candidate,
ProscaVax™, is a novel prostate cancer vaccine that’s scheduled to commence a
phase II clinical trial in the coming weeks after recording promising results
in its phase I clinical trial, which was completed late last year.
Unlike many leading treatment options, ProscaVax is being
developed to treat prostate cancer in its early stages, allowing patients to
build up an immunity that helps their bodies combat the disease with little or
no toxicity. OncBioMune’s revolutionary technology introduces molecules known
as antigens into the body in order to stimulate an aggressive immune response
before the cancer becomes too advanced. In its phase I clinical trial of
ProscaVax, an impressive 70 percent of patients who received three vaccines
demonstrated increased immune response to prostate-specific antigen (PSA), a
protein produced by cells of the prostate gland that can aid in the early
detection of prostate cancer. This result, in addition to the candidate’s
exemplary safety profile, bodes well for ProscaVax moving forward.
Leveraging a proprietary vaccine technology designed to
boost the immune system’s natural ability to protect the body, ProscaVax is
expected to be marketable and extremely profitable upon FDA approval,
potentially becoming the standard of care for prostate cancer treatment.
According to data from the American Cancer Society, about 220,800 new cases of
prostate cancer were diagnosed in the United States last year. In total, the
disease accounts for more than 27,500 deaths each year, making it the second
leading cause of cancer death in American men.
Despite its prevalence, prostate cancer remains one of the
most survivable forms of cancer, with a 10-year survival rate of roughly 98
percent in cases discovered in the local or regional stages. However,
survivability is greatly impacted if the disease goes undetected into an
advanced stage. In cases where prostate cancer has spread to bones, organs or
distant lymph nodes, the five-year survival rate drops from nearly 100 percent
to just 28 percent, according to ZERO. This statistic further highlights the potential
benefit of ProscaVax, particularly in early stage prostate cancer cases.
Leading market research firm BCC Research valued the global
market for the prevention and treatment of prostate cancer at $26.1 billion in
2011, and the firm forecasts the market to surpass $50 billion by next year.
This growth will be led by the drug therapeutics sector, which is expected to
sustain an 18 percent compound annual growth rate through 2017. As OncBioMune
prepares to commence its phase II clinical trial of ProscaVax, this market
performance could foreshadow an opportunity for the company to achieve strong
financial growth following FDA approval and commercialization of its innovative
treatment option.
Through an agreement with Lincoln Park Capital Fund,
OncBioMune has secured $10 million in funding with which to help finance the
upcoming phase II clinical study of ProscaVax. This strong cash position, along
with the early promise of the company’s cancer vaccine technologies, makes
OncBioMune an attractive play in the rapidly evolving oncology space.
For more information, visit www.oncbiomune.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
